0000950170-24-067359.txt : 20240531
0000950170-24-067359.hdr.sgml : 20240531
20240531163004
ACCESSION NUMBER: 0000950170-24-067359
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240529
FILED AS OF DATE: 20240531
DATE AS OF CHANGE: 20240531
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Inhibrx, Inc.
CENTRAL INDEX KEY: 0001739614
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-42031
FILM NUMBER: 241010200
BUSINESS ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 795-4220
MAIL ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibrx Biosciences, Inc.
CENTRAL INDEX KEY: 0002007919
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 990613523
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 795-4220
MAIL ADDRESS:
STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: Ibex SpinCo, Inc.
DATE OF NAME CHANGE: 20240111
4
1
ownership.xml
4
X0508
4
2024-05-29
true
0002007919
Inhibrx Biosciences, Inc.
INBX
0001739614
Inhibrx, Inc.
C/O INHIBRX BIOSCIENCES, INC.
11025 N. TORREY PINES ROAD, SUITE 200
LA JOLLA
CA
92037
false
false
true
false
false
Common Stock, par value $0.0001 per share
2024-05-29
4
J
false
13316140
D
1157926
D
On January 8, 2024, Inhibrx, Inc. ("RemainCo"), acquired 100 shares, par value $0.0001 per share (the "Common Stock"), of Inhibrx Biosciences, Inc. (the "Issuer"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer.
On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024.
/s/ Martin Travers, Authorized Signatory on behalf of Inhibrx, Inc.
2024-05-31